The PESGA Trial: A prospective, open-label, single-arm, phase II study to evaluate first line therapy for extensive-stage small cell lung cancer (ES-SCLC) patients, treated by induction carboplatin/etoposide/pembrolizumab followed by maintenance of pembrolizumab/ sacituzumab govitecan